Protein and lipid kinases stand in the spotlight of academic and industrial research. The launched drugs Gefitinib, Erlotinib, and Gleevec have already helped to save thousands of lives by inhibiting specific kinases leading to the reduction of cancer growth. Besides cancer, the inhibition of kinases may be the key to the treatment of other diseases, including neurological and autoimmune diseases. Due to their critical role in cellular signaling, protein kinases have been one of the most popular targets  for drug discovery. Since the determination of the atomic structure of the first human kinase more than 20 years ago, and the publication of the human kinome more than 10 years ago, a huge amount of research has been done to understand kinase biology and to find ways of targeting these enzymes to treat diseases.

Over the last 18 years biannual IPK in Warsaw, organized and mentored by Prof. David Shugar, brought together the top international kinase researchers from academia and industry. The conference featured first discoveries of novel kinase inhibitors (e.g. BIRB-796 in 2001), kinase drug discovery stories (e.g. Gleevec), innovative technologies (e.g. ASKA kinase/Prof. Kevan Shokat), novel concepts (kinase spine, types of kinase inhibitors), breakthrough structural data (Prof. Stefan Knapp), featured Nobel prize laureates (Prof. Robert Huber), popularized and broadened interest of kinase inhibitors in infectious diseases (Prof. Christian Doerig). Furthermore, the conference has been a starting point for multiple collaborations and equally important it served as an education for hundreds of students, postdocs and early-stage researchers.

All previous conferences were featured in special issues of the journals (1-8) generating highly impactful series of 211 academic papers (listed in supplementary material) with over 12377 citations (source: CALPLUS). Multiple articles from the conference proceedings achieved citation classic status with most cited paper (9) having over 800 citations (Google Scholar).

The conference goal in 2019 is to present current “hot topics” in kinase research, while retaining the focus on  the basic biology of kinases and their role in diseases. We plan to broaden the topics to include novel trends in kinase inhibition through the use of antibodies, drug conjugates and biomolecules.

Our long-term goal as organizers is to create a legacy of meetings that foster scientific interactions and industry-academic collaborations. Furthermore, we wish to contribute to the training of young scientists and thus three short oral presentations are tentatively reserved for remarkable young researchers active at Ochota Scientific Campus.

The last day of the conference will be dedicated to the memory of Professor David Shugar (1915-2015), who should be regarded as the creator of the Polish school of molecular biophysics. He has co-authored over three hundred publications, cited ~8000 times. We have a pleasure to invite his collaborators, majority of whose interests is related to the various kinase projects, and also his scientific successors (mainly former students at Biophysics Department of University of Warsaw) diffused throughout the world.

Comments are closed